Girardi Fabio, Allemani Claudia, Coleman Michel P
Cancer Survival Group, Non-Communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine, London, UK.
JNCI Cancer Spectr. 2020 Jun 10;4(5):pkaa049. doi: 10.1093/jncics/pkaa049. eCollection 2020 Oct.
Brain tumors represent an important cause of cancer-related death in adolescents and young adults. Most are diagnosed in low-income and middle-income countries. We aimed to conduct the first, to our knowledge, systematic review of time trends and geographical variation in survival in this age group.
We included observational studies describing population-based survival from astrocytic tumors in patients aged 15-39 years. We queried 6 electronic databases from database inception to December 31, 2019. This review is registered with PROSPERO, number CRD42018111981.
Among 5640 retrieved records, 20 studies fulfilled the inclusion criteria. All but 1 study focused on high-income countries. Five-year survival from astrocytoma (broad morphology group) mostly varied between 48.0% and 71.0% (1973-2004) without clear trends or geographic differences. Adolescents with astrocytoma had better outcomes than young adults, but survival values were similar when nonmalignant tumors were excluded. During 2002-2007, 5-year survival for World Health Organization grade I-II tumors was in the range of 72.6%-89.1% in England, Germany, and the United States but lower in Southeastern Europe (59.0%). Five-year survival for anaplastic astrocytoma varied between 39.6% and 55.4% (2002-2007). Five-year survival from glioblastoma was in the range of 14.2%-23.1% (1991-2009).
Survival from astrocytic tumors remained somewhat steady over time, with little change between 1973 and 2009. Survival disparities were difficult to examine, because nearly all the studies were conducted in affluent countries. Studies often adopted the International Classification of Childhood Cancer, which, however, did not allow to accurately describe variation in survival. Larger studies are warranted, including underrepresented populations and providing more recent survival estimates.
脑肿瘤是青少年和青年癌症相关死亡的重要原因。大多数病例在低收入和中等收入国家被诊断出来。据我们所知,我们旨在首次对该年龄组生存的时间趋势和地理差异进行系统评价。
我们纳入了描述15 - 39岁患者星形细胞瘤基于人群生存情况的观察性研究。我们检索了从数据库建立到2019年12月31日的6个电子数据库。本评价已在国际系统评价注册库(PROSPERO)注册,注册号为CRD42018111981。
在检索到的5640条记录中,20项研究符合纳入标准。除1项研究外,所有研究均聚焦于高收入国家。星形细胞瘤(宽泛形态学组)的5年生存率大多在48.0%至71.0%之间(1973 - 2004年),无明显趋势或地理差异。患星形细胞瘤的青少年比青年成人预后更好,但排除非恶性肿瘤后生存值相似。在2002 - 2007年期间,世界卫生组织I - II级肿瘤在英格兰、德国和美国的5年生存率在72.6% - 89.1%范围内,但在东南欧较低(59.0%)。间变性星形细胞瘤的5年生存率在39.6%至55.4%之间(2002 - 2007年)。胶质母细胞瘤的5年生存率在14.2% - 23.1%范围内(1991 - 2009年)。
星形细胞瘤的生存率随时间保持相对稳定,1973年至2009年间变化不大。生存差异难以考察,因为几乎所有研究都在富裕国家进行。研究常采用儿童癌症国际分类法,然而,该分类法无法准确描述生存差异情况。有必要开展更大规模的研究,纳入代表性不足的人群并提供更新的生存估计。